IMVT Stock Price, Immunovant Inc Quote, Chart

Market Summary

USD28.96+0.35

Delayedas of 24 Apr 2024, 11:13 am

1.22%

IMVT Alerts

5 major insider sales recently.

IMVT Stock Price

View Fullscreen

IMVT RSI Chart

IMVT Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

-17.07

EV/EBITDA

-15.48

Price/Free Cashflow

-19.74

MarketCap/EBT

-17.03

IMVT Price/Sales (Trailing)

IMVT Profitability

Return on Equity

-35.84%

Return on Assets

-34.22%

Free Cashflow Yield

-5.07%

IMVT Fundamentals

IMVT Earnings

Earnings (TTM)

-243.4M

Earnings Growth (Yr)

18.68%

Earnings Growth (Qtr)

12.35%

Breaking Down IMVT Revenue

52 Week Range

15.9044.19

(Low)(High)

Last 7 days

-5.7%

Last 30 days

-11.0%

Last 90 days

-25.8%

Trailing 12 Months

79.9%

How does IMVT drawdown profile look like?

IMVT Financial Health

Current Ratio

22.14

IMVT Investor Care

Shares Dilution (1Y)

11.55%

Diluted EPS (TTM)

-1.84

Tracking the Latest Insider Buys and Sells of Immunovant Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	salzmann peter	sold	-990,269	29.058	-34,079	chief executive officer
Apr 17, 2024	levine mark s.	sold	-285,554	29.0581	-9,827	chief legal officer
Apr 17, 2024	barnett eva renee	sold	-356,049	29.0581	-12,253	chief financial officer
Apr 17, 2024	butchko julia g.	sold	-293,923	29.0581	-10,115	chief development officer
Apr 17, 2024	macias william l.	sold	-240,602	29.0582	-8,280	chief medical officer
Apr 09, 2024	salzmann peter	sold	-149,882	31.18	-4,807	chief executive officer
Apr 09, 2024	barnett eva renee	sold	-115,023	31.18	-3,689	chief financial officer
Apr 09, 2024	butchko julia g.	sold	-32,832	31.18	-1,053	chief development officer
Apr 02, 2024	butchko julia g.	acquired	-	-	54,978	chief development officer
Apr 02, 2024	macias william l.	acquired	-	-	54,978	chief medical officer

Which funds bought or sold IMVT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	106,504	1,199,740	0.01%
Apr 19, 2024	Red Tortoise LLC	unchanged	-	-2,376	7,819	-%
Apr 19, 2024	Cutler Group LLC / CA	new	-	64,000	64,000	0.02%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	51.85	297,188	2,103,090	-%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	-116,269	382,550	0.05%
Apr 12, 2024	DNB Asset Management AS	new	-	301,517	301,517	-%
Apr 11, 2024	Fortitude Family Office, LLC	sold off	-100	-885	-	-%
Apr 05, 2024	CWM, LLC	added	2,550	2,000	2,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	39.24	678	3,554	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	185	252,160	464,327	-%

Are Funds Buying or Selling IMVT?

Are funds buying IMVT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMVT

No. of Funds

IMVT Alerts

5 major insider sales recently.

Unveiling Immunovant Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	0.69%	1e+06	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Oct 04, 2023	roivant sciences ltd.	55.3%	79,815,331	SC 13D/A
Feb 14, 2023	deep track capital, lp	7.52%	9,710,000	SC 13G/A
Dec 05, 2022	rtw investments, lp	0.0%	0	SC 13G/A
Dec 02, 2022	rtw investments, lp	5.87%	7,592,253	SC 13G/A
Feb 11, 2022	deep track capital, lp	5.83%	6,780,827	SC 13G
Aug 02, 2021	roivant sciences ltd.	63.8%	73,398,664	SC 13D/A
Mar 08, 2021	roivant sciences ltd.	57.5%	56,377,388	SC 13D/A
Feb 16, 2021	rtw investments, lp	7.75%	7,592,253	SC 13G/A

Recent SEC filings of Immunovant Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 15, 2024	S-8	Employee Benefits Plan
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading

Peers (Alternatives to Immunovant Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Immunovant Inc News

Latest updates

Immunovant Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	143.6%	711	292	351	406	456	428	459	516	543	567	388	412	433	454	290	109	127	24.00	117	14.00	-
Current Assets	144.1%	711	291	350	404	454	426	456	513	540	564	385	409	429	450	286	109	127	22.00	2.00	13.00	0.00
Cash Equivalents	156.0%	691	270	330	377	433	406	427	494	527	559	379	400	422	444	280	101	124	19.00	4.00	7.00	12.00
Net PPE	23.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	-
Liabilities	-20.3%	32.00	40.00	51.00	43.00	42.00	32.00	22.00	46.00	38.00	30.00	22.00	21.00	19.00	15.00	23.00	15.00	15.00	47.00	4.00	6.00	0.00
Current Liabilities	-20.3%	32.00	40.00	51.00	43.00	41.00	32.00	21.00	45.00	36.00	28.00	21.00	19.00	16.00	13.00	20.00	15.00	-	0.00	0.00	0.00	0.00
Shareholder's Equity	169.8%	679	252	300	362	415	396	436	470	505	536	366	391	414	438	268	94.00	112	5.00	5.00	7.00	8.00
Retained Earnings	-7.4%	-750	-698	-640	-566	-506	-443	-395	-355	-308	-266	-229	-198	-170	-138	-117	-91.23	-70.67	-59.38	0.00	-24.84	-448*
Additional Paid-In Capital	50.5%	1,430	950	940	928	920	841	833	825	813	803	594	590	584	577	386	185	183	36.00	5.00	32.00	0.00
Shares Outstanding	10.4%	145	131	131	130	129	117	117	116	107	109	98.00	98.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	239	-	-	-	347	-	-	-	1,461	-	-	-	115	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	21.6%	-47,098	-60,060	-47,370	-55,793	-46,395	-20,186	-65,819	-32,956	-31,895	-20,047	-21,214	-22,496	-22,815	-24,218	-13,798	-23,050	-4,418	-301	-8,332	-450*	-7,387
Share Based Compensation	-2.9%	10,220	10,529	10,688	7,546	8,906	8,157	7,687	11,863	10,159	8,361	3,861	5,488	5,992	3,361	3,981	1,840	1,414	3,137	572	233	236
Cashflow From Investing	-285.3%	-131	-34.00	-45.00	-26.00	-98.00	-31.00	-42.00	-118	-74.00	-44.00	-18.00	-95.00	-29.00	-39.00	-47.00	-10.00	-13.00	-4.00	-	-	-
Cashflow From Financing	317362.2%	469,844	148	890	233	70,631	-	21.00	-	-	200,038	91.00	763	446	188,350	193,553	101	108,969	32,601	5,303	-176	14,496

IMVT Income Statement

2023-12-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 48,338	$ 42,252	$ 146,872	$ 108,420
Acquired in-process research and development	0	10,000	12,500	10,000
General and administrative	13,215	11,775	42,458	35,597
Total operating expenses	61,553	64,027	201,830	154,017
Interest income	(8,933)	(2,944)	(16,569)	(4,098)
Other (income) expense, net	(1,094)	1,757	(1,579)	609
Loss before provision (benefit) for income taxes	(51,526)	(62,840)	(183,682)	(150,528)
Provision (benefit) for income taxes	(108)	387	335	1,000
Net loss	$ (51,418)	$ (63,227)	$ (184,017)	$ (151,528)
Net loss per common share - basic (in dollars per share)	$ (0.36)	$ (0.49)	$ (1.36)	$ (1.26)
Net loss per common share - diluted (in dollars per share)	$ (0.36)	$ (0.49)	$ (1.36)	$ (1.26)
Weighted-average common shares outstanding – basic (in shares)	144,523,034	128,574,190	135,577,267	120,665,299
Weighted-average common shares outstanding – diluted (in shares)	144,523,034	128,574,190	135,577,267	120,665,299

IMVT Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 690,937	$ 376,532
Accounts receivable	1,029	700
Prepaid expenses and other current assets	18,810	27,101
Total current assets	710,776	404,333
Operating lease right-of-use assets	294	1,172
Property and equipment, net	376	333
Total assets	711,446	405,838
Current liabilities:
Accounts payable	3,910	1,353
Accrued expenses	27,886	40,771
Current portion of operating lease liabilities	306	1,173
Total current liabilities	32,102	43,297
Operating lease liabilities, net of current portion	0	47
Total liabilities	32,102	43,344
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 145,094,052 shares issued and outstanding at December 31, 2023 and 500,000,000 shares authorized, 130,329,863 shares issued and outstanding at March 31, 2023	14	13
Additional paid-in capital	1,430,294	927,976
Accumulated other comprehensive (loss) income	(600)	852
Accumulated deficit	(750,364)	(566,347)
Total stockholders’ equity	679,344	362,494
Total liabilities and stockholders’ equity	711,446	405,838
Series A preferred stock
Stockholders’ equity:
Preferred stock	0	0
Preferred Stock
Stockholders’ equity:
Preferred stock	$ 0	$ 0

About Immunovant Inc

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

CEO	Dr. Peter Salzmann M.B.A., M.D.
WEBSITE	https://immunovant.com
INDUSTRY	Biotechnology
EMPLOYEES	164

Immunovant Inc Frequently Asked Questions

What is the ticker symbol for Immunovant Inc? What does IMVT stand for in stocks?

IMVT is the stock ticker symbol of Immunovant Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immunovant Inc (IMVT)?

As of Tue Apr 23 2024, market cap of Immunovant Inc is 4.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMVT stock?

You can check IMVT's fair value in chart for subscribers.

What is the fair value of IMVT stock?

You can check IMVT's fair value in chart for subscribers. The fair value of Immunovant Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immunovant Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMVT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immunovant Inc a good stock to buy?

The fair value guage provides a quick view whether IMVT is over valued or under valued. Whether Immunovant Inc is cheap or expensive depends on the assumptions which impact Immunovant Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMVT.